Abstract: Objective: To observe the therapeutic effect of the conprata pulean in the treatment of benign prostate hyperplasia.Methods: A total of 80 patients with symptomatic benign prostatic hyperplasia were made a definite diagnosis at outpatient and randomly divided into two groups: 60 patients of treatment group were treated with conprata pulean 3 tablet,po,tid;20 patients in the control group,finateride with 1 tablet,po,qd;All patients received 90 days as a course of treatment.The therapeutic results were assessed before and after the treatment by using following variables:the safety and efficacy of conprata pulean,international prostatic symptom score（IPSS）,quality of life（QOL）,postvoid residual urine volume（RUV）,mean Qmax.Results: The conprata pulean was safe and effective relief for patients with obstructive BPH.The total effective rates was 93.3% in the conprata pulean group.All patients were followed up for 3months in the conprata pulean group.IPSS and QOL was decreased from 14.4±3.8 and 3.1±0.6 to 10.0±2.7 and 1.7±0.6,Qmax increased from 13.2±1.9ml/s to 17.5±4.7ml/s,respectively.There were significant differences of these parameters before and after treatment（P＜0.05）,there was no significent difference between two groups（P＞0.05）.There were no significant differences RUV,prostate volume and PSA.Conclusion: Conprata pulean is an ideal drug in the treatment of BPH patients with obstructive symptom at present.